Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
pathway

PepT1 transporter

also: PepT1, SLC15A1, peptide transporter 1, PEPT1

A proton-dependent di/tripeptide transporter on intestinal epithelial cells that takes up dietary di- and tripeptides and some peptide-like drugs across the gut lining.

PepT1 (peptide transporter 1, gene SLC15A1) is an electrogenic, proton-coupled symporter (it moves peptides and protons in the same direction) expressed at high levels on the apical (luminal) membrane of small intestinal enterocytes, with lower expression in renal tubular epithelium and bile duct epithelium. It functions as the primary transporter for dietary di- and tripeptides generated by luminal proteolysis, mediating their uptake into absorptive cells together with protons, with the proton gradient across the membrane driving the transport.

Why it matters in peptide research

PepT1 carries only very short peptides, two or three amino acids long, and it also carries some peptide-like drugs. A peptide that is not a di- or tripeptide is not a PepT1 substrate, so the transporter says nothing about whether longer research peptides are absorbed after swallowing.

For a di- or tripeptide, being a PepT1 substrate is not the same as being absorbed in a form that reaches the blood or a target tissue. The peptide also has to survive stomach acid and gut enzymes, and the exposure has to be measured, rather than inferred from an effect.

Peptides that act on this

  • KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH. In cultured human cells it is taken up through PepT1, and KPV in the drinking water of mice reduced colitis. A 2026 study found free KPV almost completely hydrolysed in simulated gastric and intestinal fluid, and no study we found measured intact KPV in blood or tissue after oral dosing. The details are in the KPV evidence summary.
  • Beta-lactam antibiotics and ACE inhibitor prodrugs, classic examples of peptide-like drugs that use PepT1.

Reading tip

When you meet a claim that a peptide can be taken by mouth, ask three questions. Is it a di- or tripeptide? Does a published study show that it is a PepT1 substrate? Was the peptide itself measured in blood or tissue after oral dosing, rather than only an effect seen in an animal? Answering these separates a plausible mechanism from a measured result.

Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the claim that oral KPV reaches 'meaningful intestinal tissue concentrations via PepT1' was replaced by cell and mouse findings, a 2026 study of free KPV hydrolysed in simulated gut fluid, and the lack of any measurement of intact KPV after oral dosing.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Related glossary entries

Continue reading